A New Oral BTK Protein Degrader: A novel drug designed to overcome resistance to BTK Inhibitors
Featuring Dr. Brian Koffman and Dr. Adrian Wiestner
For more information on the Clinical Trial, please visit: https://cllsociety.org/treatment-and-research/clinical-trials/
Find CLL Society on Social Media
Follow CLL Society on Facebook @CLLSociety as well as other social media platforms below.